Post by
BaystreetBrian on Dec 18, 2014 7:32am
QUOTED DIRECTLY FROM THE ARTICLE!!!!
"NPS is required to submit a Risk Evaluation and Mitigation Strategy (REMS) for Natpara; however, no further clinical studies are required for the hormone replacement therapy. Therefore, NPS looks likely to receive the necessary regulatory approvals for Natpara soon."
"Shire may end up extending an acquisition bid to NPS even before a ruling is made on Natpara."